Do new, prospective data mean the 4KScore test is “proven” for use in prime time?

According to data from a large, prospective, multi-institutional trial carried out here in the USA, the 4KScore test has shown a high degree of ability to accurately identify men with a Gleason score of 3 + 4 = 7 or higher which was subsequently confirmed on prostate biopsy. … READ MORE …

A rising incidence of intermediate- and higher-risk prostate cancer … but what does this mean?

According to another paper to be presented at the Genitourinary Cancers Symposium in Orlando, Florida, that started this morning, there was a 6 percent increase in the proportion of patients being diagnosed with intermediate- or higher-risk prostate cancers between 2011 and 2013. … READ MORE …

Active surveillance is absolutely NOT appropriate for all men with intermediate-risk prostate cancer

A paper to be presented this Thursday at the upcoming Genitourinary Cancers Symposium in  Orlando, Florida, will clearly confirm the above heading, which should come as no surprise to anyone. The issue has always been whether there is a subset of men with (“favorable”) intermediate-risk disease who are potentially appropriate candidates. … READ MORE …

Is active surveillance appropriate for men with favorable intermediate-risk prostate cancer?

In a paper in the first issue of the new journal JAMA Oncology, a group of US-based researchers argue that data from a series of > 5,000 patients treated with first-line brachytherapy suggest that men with favorable intermediate-risk prostate cancer are actually good candidates for active surveillance. … READ MORE …

Risk for radiation-induced second primary cancer (RTSPC) is low and may differ by radiation technique

While radiation therapy cures many cancers, many men worry that radiation-induced sub-lethal damage to healthy tissue may someday result in a second primary cancer in the irradiated field. … READ MORE …

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …

Will “Apifiny” be helpful in the diagnosis of prostate cancer?

The development-stage test known as Apifiny is a new type of test that its creators believe will help in the more accurate diagnosis of prostate cancer. Whether that is actually the case seems to be rather less certain as yet. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,241 other followers